Clinical trial
CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies
NCT03383055 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 16, 2018
- Completion date
- July 10, 2021
- Enrollment
- 28 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.